NASDAQ:BMRABiomerica Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.60 -0.47 (-6.65 %) (As of 04/3/2020 04:00 PM ET) Add Compare Share Today's Range$6.30Now: $6.60▼$7.2350-Day Range$2.37MA: $4.37▼$16.0052-Week Range$2.05Now: $6.60▼$23.39Volume1.06 million shsAverage Volume1.29 million shsMarket Capitalization$65.27 millionP/E RatioN/ADividend YieldN/ABeta-0.9 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations. It primarily offers its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the point-of-care and in-hospital/clinical laboratories worldwide. The company is also developing InFoods, an irritable bowel syndrome (IBS) therapy technology and diagnostic-guided therapy, which is in clinical studies to identify specific foods that when removed from the patient's diet can alleviate the patient's IBS symptoms. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.Read More Beat the Market (BTM) Rank™ 1.5 Analyst's Opinion Consensus RatingBiomerica has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.30, Biomerica has a potential downside of 4.5% from its current price of $6.60.Amount of Analyst CoverageBiomerica has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesBiomerica has received 124 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBiomerica has received 129 “underperform” votes. (Add your “underperform” vote.)Community SentimentBiomerica has received 50.99% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Biomerica and other stocks. Vote “Outperform” if you believe BMRA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMRA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBiomerica does not currently pay a dividend.Dividend GrowthBiomerica does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biomerica insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 25.70% of the stock of Biomerica is held by insiders.Percentage Held by InstitutionsOnly 2.37% of the stock of Biomerica is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Biomerica are expected to decrease by -16.67% in the coming year, from ($0.24) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomerica is -26.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomerica is -26.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomerica has a P/B Ratio of 16.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.80 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BMRA Previous Symbol CUSIPN/A CIK73290 Webhttp://www.biomerica.com/ Phone949-645-2111Debt Debt-to-Equity Ratio0.50 Current Ratio2.27 Quick Ratio1.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$5.20 million Price / Sales12.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book16.10Profitability EPS (Most Recent Fiscal Year)($0.26) Net Income$-2,390,000.00 Net Margins-47.06% Return on Equity-65.75% Return on Assets-40.79%Miscellaneous Employees54 Outstanding Shares9,890,000Market Cap$65.27 million Next Earnings Date4/20/2020 (Estimated) OptionableNot Optionable Receive BMRA News and Ratings via Email Sign-up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BMRA Rates by TradingView Biomerica (NASDAQ:BMRA) Frequently Asked Questions How has Biomerica's stock been impacted by COVID-19 (Coronavirus)? Biomerica's stock was trading at $2.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BMRA shares have increased by 127.6% and is now trading at $6.60. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Biomerica? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomerica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Biomerica. When is Biomerica's next earnings date? Biomerica is scheduled to release its next quarterly earnings announcement on Monday, April 20th 2020. View our earnings forecast for Biomerica. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) released its earnings results on Wednesday, January, 15th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.08) by $0.03. The company earned $1.60 million during the quarter, compared to analysts' expectations of $1.69 million. Biomerica had a negative net margin of 47.06% and a negative return on equity of 65.75%. View Biomerica's earnings history. What price target have analysts set for BMRA? 1 Wall Street analysts have issued 1 year target prices for Biomerica's stock. Their forecasts range from $6.30 to $6.30. On average, they expect Biomerica's stock price to reach $6.30 in the next twelve months. This suggests that the stock has a possible downside of 4.5%. View analysts' price targets for Biomerica. Has Biomerica been receiving favorable news coverage? Media headlines about BMRA stock have been trending very negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biomerica earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutBiomerica. Are investors shorting Biomerica? Biomerica saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,700 shares, an increase of 22.7% from the February 27th total of 2,200 shares. Based on an average daily trading volume, of 43,700 shares, the short-interest ratio is presently 0.1 days. Approximately 0.0% of the company's stock are short sold. View Biomerica's Current Options Chain. Who are some of Biomerica's key competitors? Some companies that are related to Biomerica include Straumann (SAUHF), DENTSPLY SIRONA (XRAY), Sartorius (SARTF), SmileDirectClub (SDC), BIOLASE (BIOL) and Remedent (REMI). What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Accenture (ACN), Corbus Pharmaceuticals (CRBP), General Motors (GM), Agenus (AGEN), Akers Biosciences (AKER), T2 Biosystems (TTOO), AbbVie (ABBV), Eastman Chemical (EMN), Ford Motor (F) and Kohl's (KSS). Who are Biomerica's key executives? Biomerica's management team includes the following people: Mr. Zackary S. Irani, Chairman & CEO (Age 53)Ms. Janet Moore, CFO, Treasurer, Sec. & Director (Age 68) What is Biomerica's stock symbol? Biomerica trades on the NASDAQ under the ticker symbol "BMRA." How do I buy shares of Biomerica? Shares of BMRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Biomerica's stock price today? One share of BMRA stock can currently be purchased for approximately $6.60. How big of a company is Biomerica? Biomerica has a market capitalization of $65.27 million and generates $5.20 million in revenue each year. The company earns $-2,390,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. Biomerica employs 54 workers across the globe. View additional information about Biomerica. What is Biomerica's official website? The official website for Biomerica is http://www.biomerica.com/. How can I contact Biomerica? Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company can be reached via phone at 949-645-2111. This page was last updated on 4/3/2020 by MarketBeat.com StaffFeatured Article: Earnings Reports
